SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-17472"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-17472" > Treatment with Comb...

Treatment with Combined Streptozotocin and Liposomal Doxorubicin in Metastatic Endocrine Pancreatic Tumors

Fjällskog, Marie-Louise H., (författare)
Uppsala universitet, Institutionen för onkologi, radiologi och klinisk immunologi, Bröstgruppen
Janson, Eva Tiensuu, (författare)
Uppsala universitet, Institutionen för medicinska vetenskaper, Onkologisk endokrinologi
Falkmer, Ursula G. (författare)
visa fler...
Vatn, Morten H. (författare)
Öberg, Kjell E., (författare)
Uppsala universitet, Institutionen för medicinska vetenskaper, Onkologisk endokrinologi
Eriksson, Barbro K., (författare)
Uppsala universitet, Institutionen för medicinska vetenskaper, tumörbiologisk endokrinologi
visa färre...
 
2008
Engelska.
Ingår i: Neuroendocrinology. - 0028-3835 .- 1423-0194. ; 88:1, s. 53-8
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • <p>Treatment with combined streptozotocin and liposomal doxorubicin is safe and efficient in patients with endocrine pancreatic tumors (EPTs). No cardiac toxicity was reported. BACKGROUND: The combination of streptozotocin and doxorubicin has been shown to be superior to streptozotocin and fluorouracil in the treatment of metastatic EPTs. However, the risk of cardiac toxicity from anthracyclins hampers the usefulness of the drug combination. Liposomal doxorubicin has a lower frequency of cardiac adverse events compared to doxorubicin. We wanted to assess the efficacy and safety of combined streptozotocin and liposomal doxorubicin in patients with metastatic EPTs. METHODS: Thirty patients with metastatic EPTs were recruited from three medical centers in Norway and Sweden during a time period of 3 years. All patients had histopathologically confirmed diagnoses and bidimensionally measurable lesions. 30 mg/m(2) of liposomal doxorubicin was administered on day 1 of each cycle. During the first course, 1 g of streptozotocin was given on 5 consecutive days. Thereafter, 2 g of streptozotocin was given on day 1 only. Treatment was repeated every 3 weeks. RESULTS: Twelve of 30 patients (40%) achieved an objective radiological response with a median duration of 9 months. Stabilization of disease was achieved in 17 of 30 patients (57%) for a median duration of 11 months. Only one patient had progressive disease as best response. The 2-year progression-free survival was 18% and the 2-year overall survival was 72%. The treatment was well tolerated. None of the patients experienced cardiac toxicity. CONCLUSION: We conclude that combined streptozotocin and liposomal doxorubicin is a safe and efficient treatment for EPTs. The efficacy seems to be comparable to that of combined streptozotocin and doxorubicin, whereas the cardiac toxicity clearly favors using the liposomal drug combination. 2008 S. Karger AG, Basel.</p>

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  (hsv//swe)
MEDICAL AND HEALTH SCIENCES  (hsv//eng)

Nyckelord

Neuroendocrine tumors
Streptozotocin
Liposomal doxorubicin
Cardiotoxicity
MEDICINE
MEDICIN

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy